Avacta reports 2025 results, raises £32.5m for oncology trials

Biotech Firm Raises Funds for Cancer Research Avacta Group has reported its 2025 financial results, securing £32.5 million to support oncology trials. The funds will be used to advance the company's cancer research and development efforts. The investment is a significant boost for Avacta's ongoing work in the field of precision medicine.